title: TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.
abstract: Inozume et al. describe a novel immunosuppressive mechanism in melanoma that is triggered by the interaction between CD155 (expressed by melanomas) and T-cell Ig and ITIM domain (TIGIT) (expressed by tumor infiltrating lymphocytes). This pathway exists in addition to the "classical" co-inhibitory PD-1-PD-L1 pathway. Hence, the combinatorial blockage of both pathways by specific antibodies resulted in the greatly enhanced effector function of melanoma-specific cytotoxic T cells. Given that CD155-TIGIT signaling exerts potent inhibitory action in different subsets of immune cells and that CD155 is expressed broadly in several tumor entities, this report points toward a novel and promising therapeutic strategy to combine different checkpoint blocking agents for greater success in antitumor therapy.
authors.affiliation: Department of Dermatology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. Electronic address: karsten.mahnke@med.uni-heidelberg.de.
authors.forename: Karsten
authors.initials: K
authors.lastname: Mahnke
authors.affiliation: Department of Dermatology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
authors.forename: Alexander H
authors.initials: AH
authors.lastname: Enk
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D034741:RNA, Small Interfering / Q000378:metabolism*; D011971:Receptors, Immunologic / Q000378:metabolism*; D011991:Receptors, Virus / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D034741:RNA, Small Interfering; D011971:Receptors, Immunologic; D011991:Receptors, Virus